Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Total Valuation
Fulcrum Therapeutics has a market cap or net worth of $533.47M. The enterprise value is $242.34M.
Market Cap$533.47M
Enterprise Value$242.34M
Share Statistics
Fulcrum Therapeutics has 66,600,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,600,210
Owned by Insiders10.33%
Owned by Institutions17.24%
Financial Efficiency
Fulcrum Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -23.84%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-23.84%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee0.00
Profits Per Employee-1.66M
Employee Count45
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fulcrum Therapeutics is ―. Fulcrum Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.05
Price to Fair Value2.05
Price to FCF-11.87
Price to Operating Cash Flow-8.45
PEG Ratio-0.02
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 0.00 and earned -74.88M in profits. Earnings per share was -1.18.
Revenue0.00
Gross Profit-1.39M
Operating Income-84.77M
Pretax Income-74.88M
Net Income-74.88M
EBITDA-73.49M
Earnings Per Share (EPS)-1.18
Cash Flow
In the last 12 months, operating cash flow was -60.06M and capital expenditures -314.00K, giving a free cash flow of -60.38M billion.
Operating Cash Flow-60.06M
Free Cash Flow-60.38M
Free Cash Flow per Share-0.91
Dividends & Yields
Fulcrum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.91
52-Week Price Change170.61%
50-Day Moving Average10.10
200-Day Moving Average8.76
Relative Strength Index (RSI)35.73
Average Volume (3m)919.40K
Important Dates
Fulcrum Therapeutics upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Fulcrum Therapeutics as a current ratio of 27.40, with Debt / Equity ratio of 1.85%
Current Ratio27.40
Quick Ratio27.40
Debt to Market Cap<0.01
Net Debt to EBITDA2.60
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fulcrum Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fulcrum Therapeutics EV to EBITDA ratio is -7.15, with an EV/FCF ratio of -8.70.
EV to Sales0.00
EV to EBITDA-7.15
EV to Free Cash Flow-8.70
EV to Operating Cash Flow-8.75
Balance Sheet
Fulcrum Therapeutics has $352.31M in cash and marketable securities with $6.44M in debt, giving a net cash position of $345.86M billion.
Cash & Marketable Securities$352.31M
Total Debt$6.44M
Net Cash$345.86M
Net Cash Per Share$5.19
Tangible Book Value Per Share$5.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Fulcrum Therapeutics is $16.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.80
Price Target Upside111.59% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast-305.92%